BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

Cerus

At Cerus Corporation we have developed a platform technology (Helinx®) that prevents nucleic acid (DNA and RNA) replication. The Company's initial application of this technology is the development of the INTERCEPT Blood Systems to inactivate viruses, bacteria and other pathogens in the blood components used for transfusion - platelets, plasma and red blood cells.


Contact Details:
2411 Stanwell Drive
Concord
CA
94520
United States of America
Tel:(925) 288-6000
Fax:(925) 288-6001
Email:customer_services@cerus.com
WWW:

www.ceruscorp.com/




Loading...

Recent Publications by Cerus:

Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components.
BACKGROUND: Transfusion-transmitted cases of malaria and babesiosis have...
28th May, 2008
Biologie Fonctionnelle des Protozoaires, Museum National d'Histoire Transfusion. 2008 Aug;48(8):1676-84. Epub 2008 May 22.
DOI Direct Link
Palladium-mediated C5 substitution of pyrimidine nucleosides.
One of the most efficient ways to link a reporter group to...
15th May, 2008
Cerus Corp., Concord, California, USA. Curr Protoc Nucleic Acid Chem. 2001 May;Chapter 1:Unit 1.1.
DOI Direct Link
Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.
NK cells can identify and eliminate emerging tumors due to altered...
6th February, 2008
Cerus Corporation, J Immunol. 2007 Dec 1;179(11):7376-84.
Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
BACKGROUND: The human erythrovirus B19 (B19) is a small (18- to 26-nm)...
7th August, 2007
Cerus Corporation, Concord, California 94520, USA. Transfusion. 2007 Jun;47(6):1062-70.
DOI Direct Link
Cytosolic entry controls CD8+-T-cell potency during bacterial infection.
Interaction with host immunoreceptors during microbial infection directly...
14th December, 2006
Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94520, USA. Infect Immun. 2006 Nov;74(11):6387-97. Epub 2006 Sep 5.
DOI Direct Link

View more Cerus research publications.

BioNews Results for Cerus:

Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of Previously Frozen Plasma
Genetic Engineering News:  Aug 12 2008 10:45AM Matching: cerus
Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of Previously Frozen Plasma
Pharma Live:  Aug 12 2008 3:17PM Matching: cerus
Cerus Corporation to Release Second Quarter Financial Results
Pharma Live:  Jul 17 2008 12:52PM Matching: cerus
Cerus Announces INTERCEPT Blood System Data Presented at International Society of Blood Transfusion Conference
Pharma Live:  Jun 9 2008 12:03PM Matching: cerus

Cerus Patents:

US Patent No.Title
5593823 Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
6004741 Method for the photoactivation of 4' and 5' primary aminoalkyl psoralens in platelet preparations
6004742 Method for inactivation of pathogens in platelets using 4' and 5' primary amino-substituted psoralens
6017691 4'-primary aminopsoralen and platelet compositions
6093725 Frangible compounds for pathogen inactivation

View more Cerus patents.

Cerus (CERS) Financial information Links from Barchart

CERS Quote from from Barchart.com
CERS Chart from from Barchart.com
CERS Profile from from Barchart.com
CERS Opinion from from Barchart.com

View more Cerus finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 187 times since April 2007, the link to the organisation's website has been followed 31 times

Recent Search Terms used to find this page: intercept | Cerus | cerus | cerus | .

Search for more companies in Concord

Search for more companies in CA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Cerus
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.